http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Native Void Space for Maximum Volumetric Capacity in Silicon-Based Anodes
Yeom, Su Jeong,Lee, Cheolmin,Kang, Sujin,Wi, Tae-Ung,Lee, Chanhee,Chae, Sujong,Cho, Jaephil,Shin, Dong Ok,Ryu, Jungki,Lee, Hyun-Wook American Chemical Society 2019 NANO LETTERS Vol.19 No.12
<P>Volumetric energy density is considered a primary factor in developing high-energy batteries. Despite its significance, less efforts have been devoted to its improvement. Silicon-based materials have emerged as next-generation anodes for lithium-ion batteries due to their high specific capacity. However, their volumetric capacities are limited by the volume expansion rate of silicon, which restricts mass loading in the electrodes. To address this challenge, we introduce porous silicon templated from earth-abundant minerals with native internal voids, capable of alleviating volumetric expansion during repeated cycles. In situ transmission electron microscopy analysis allows the precise determination of the expansion rate of silicon, thus presenting an analytical model for finding the optimal content in silicon/graphite composites. The inner pores in silicon reduce problems associated with its expansion and allow higher silicon loading of 42% beyond the conventional limitations of 13-14%. Consequently, the anode designed in this work can deliver a volumetric capacity of 978 mAh cc<SUP>-1</SUP>. Thus, suppressing volume expansion with natural abundant template-assisted materials opens new avenues for cost-effective fabrication of high volumetric capacity batteries.</P> [FIG OMISSION]</BR>
포스터 전시 : 상부위장관 ; 십이지장을 침범한 Henoch-Schonlein 자반증 1예
염문선 ( Yeom Mun Seon ),심기남 ( Sim Gi Nam ),이한효 ( Lee Han Hyo ),남준식 ( Nam Jun Sig ),최희정 ( Choe Hui Jeong ),문일환 ( Mun Il Hwan ),김성은 ( Kim Seong Eun ),이지수 ( Lee Ji Su ),정성애 ( Jeong Seong Ae ),정혜경 ( Jeong H 대한소화기학회 2003 대한소화기학회 추계학술대회 Vol.2003 No.-
Henoch-Schonlein 자반증은 촉진성 자반, 관절통, 복통, 사구체신염을 특징적으로 하는 전신성 괴사성 혈관염이다. 저자들은 내원 2일전부터 생긴 하지의 자반 및 간헐적인 복통과 내원 당일에 발생한 고열을 주소로 내원하여 십이지장을 침범한 Henoch-Schonlein 자반증으로 진단된 1례를 경험하였기에 보고하는 바이다. 평소 건강히 지내던 43세 남자가 내원 2일전부터 양쪽 발부터 시작되어 다리로 확장된 자반 및 간헐적인 복통과 내원 당일에
Interim Guidelines on Antiviral Therapy for COVID-19
Kim Sun Bean,Huh Kyungmin,Heo Jung Yeon,Joo Eun-Jeong,Kim Youn Jeong,Choi Won Suk,Kim Yae-Jean,Seo Yu Bin,Yoon Young Kyung,Ku Nam Su,Jeong Su Jin,Kim Sung-Han,Peck Kyong Ran,Yeom Joon Sup 대한감염학회 2020 Infection and Chemotherapy Vol.52 No.2
Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.
Kim Sun Bean,Kim Jimin,Huh Kyungmin,Choi Won Suk,Kim Yae-Jean,Joo Eun-Jeong,Kim Youn Jeong,Yoon Young Kyung,Heo Jung Yeon,Seo Yu Bin,Jeong Su Jin,Yu Su-Yeon,Peck Kyong Ran,Choi Miyoung,Yeom Joon Sup 대한감염학회 2021 Infection and Chemotherapy Vol.53 No.2
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
Comparison in vivo knock-in strategy using dual adeno associated virus
Jeong Hyeon Lee,Dong Woo Song,Se Jun Ahn,Jeong Pil Han,Geon Seong Lee,Seok Joong Kim,Su Cheong Yeom 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
Genetic disorders with loss of function could overcome AAV-mediated gene therapy, but AAV has a limitation of capsid-mediated immunogenicity and the possibility of random integration. In contrast, genome editing offers the potential to get permanent treatment without repeated transduction. However, in vivo knock-in efficiency is extremely low; thus, a new innovative strategy to overcome this is needed. We tried to evaluate the knockin platform against human genetic disorder by inserting the protein-coding gene. In this experiment, hemophilia B was selected as a candidate genetic disorder, and the KI efficiency and therapeutic effect were verified by dual transduction of AAV-packed Campylobacter jejuni Cas9 and donor template. HR strategy did not develop any evidence of in vivo therapeutic KI, and it seemed to be reasoned by the non-dividing characteristics of target hepatocytes. In contrast, NHEJ mediated integration and bidirectional template AAV mediated integration exhibited evidence of in vivo KI and produced therapeutic functional proteins (human F9 blood concentration- NHEJ mediated KI: 50ng/ml, bidirectional AAV: 250 ng/ml). Besides, the AAV mediated integration strategy created a more precise or unbroken KI than NHEJ mediated KI. Although the reason for the incomplete KI of the HITI strategy was unclear, the AAV mediated integration would be better in vivo KI strategy than other strategies. There were also several interesting findings; 1) AAV transduction interference between dual AAVs, 2) no enhancement of KI efficiency by interval AAV transduction. We present bidirectional AAV donor template mediated KI to develop relative high and preservative therapeutic gene KI into target cell under in vivo situation.
Jeong, Hoar Lim,Jung, Yang-Sook,Jun, Jin-Su,Yeom, Jung Sook,Park, Ji Sook,Seo, Ji-Hyun,Lim, Jae-Young,Park, Chan-Hoo,Woo, Hyang-Ok,Youn, Hee-Shang,Ko, Gyung-Hyuck,Baik, Seung-Chul,Lee, Woo-Kon,Cho, My The Korean Society of Pediatric Gastroenterology 2012 Pediatric gastroenterology, hepatology & nutrition Vol.15 No.2
Purpose: Commercial enzyme-linked immunosorbent assay (ELISA) kits have been considered less reliable for children than for adults. The aim of this study was to compare four ELISA kits and in-house immunoblotting based on the analysis of anti-H. pylori-IgG antibody reactivity. Methods: A total of 399 serum samples were collected at the GNU Hospital during 1998-1999. All sera were tested using ELISA and immunoblotting. Statistically significant differences were determined by the $x^2$ test. Results: The overall seropositivity rates using GAP IgG, Genedia IgG, HM-CAP, Pyloriset EIA-G, and immunoblotting were 13.0%, 25.1%, 18.3%, 15.8%, and 62.9%, respectively. Immunoblotting showed a higher seropositivity rate than did all four ELISA kits in all age groups. Genedia IgG had the highest seropositivity among the ELISA kits. The seropositivity rate for children aged 13 to 18 months was lowest, and that of children aged 15 years was highest (90.0%). The seropositivity rate for children aged 7 months to 5 years was significantly lower than that for children aged 6 to 15 years among the four ELISA kits (p<0.0001) and immunoblotting (p=0.02). Conclusion: Immunoblotting is the most sensitive test for detection of anti-Helicobacter pylori IgG antibodies among the serological tests in this study. These results emphasize the need for standardization when commercial ELISA tests are used in different nations or in young age groups. Immunoblotting could be a suitable noninvasive assay for serodiagnosis and seroepidemiologic study of H. pylori infection in Korean children.
Biomechanical Analysis of a Novel Wedge Locking Plate in a Porcine Tibial Model
Jeong-Ku Ha,Chul Hyun Yeom,Ho Su Jang,Han-Eui Song,이성재,Kang Hee Kim,정규성,Mahendar Gururaj Bhat,김진구 대한정형외과학회 2016 Clinics in Orthopedic Surgery Vol.8 No.4
Background: The purpose of this study was to analyze biomechanical properties of a novel wedge locking plate in medial open wedge high tibial osteotomy (OWHTO) in a porcine tibial model. Methods: A uniform 8-mm OWHTO was performed in 12 porcine tibiae. Six of them were subsequently fixed with the plate without a wedge, whereas the other 6 were additionally reinforced with a metal wedge of 8 mm. Biomechanical properties (stiffness, displacement of the osteotomy gap, and failure load) were evaluated under axial load. The different modes of failure were also investigated. Results: The plate showed an axial stiffness of 2,457 ± 450 N/mm with a wedge and 1,969 ± 874 N/mm without a wedge. The maximum failure load was 5,380 ± 952 N with a wedge and 4,354 ± 607 N without a wedge. The plate with a wedge had a significantly greater failure load and significantly less displacement of medial gap at failure than that without a wedge (p = 0.041 and p = 0.002, respectively). The axial stiffness was not different between the two types of fixation. Most failures were caused by lateral cortex breakage and there was no implant failure. Conclusions: The novel wedge locking plate showed excellent biomechanical properties and an additional wedge provided significant improvement. This plate can be a good fixation method for OWHTO.